ATRA
Price
$14.15
Change
+$1.18 (+9.10%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
91.09M
CASI
Price
$1.58
Change
+$0.06 (+3.95%)
Updated
Sep 24, 04:58 PM (EDT)
Capitalization
23.55M
Interact to see
Advertisement

ATRA vs CASI

Header iconATRA vs CASI Comparison
Open Charts ATRA vs CASIBanner chart's image
Atara Biotherapeutics
Price$14.15
Change+$1.18 (+9.10%)
Volume$200
Capitalization91.09M
CASI Pharmaceuticals
Price$1.58
Change+$0.06 (+3.95%)
Volume$2.32K
Capitalization23.55M
ATRA vs CASI Comparison Chart in %
Loading...
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATRA vs. CASI commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Buy and CASI is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (ATRA: $12.97 vs. CASI: $1.52)
Brand notoriety: ATRA and CASI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 109% vs. CASI: 2%
Market capitalization -- ATRA: $91.09M vs. CASI: $23.55M
ATRA [@Biotechnology] is valued at $91.09M. CASI’s [@Biotechnology] market capitalization is $23.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileCASI’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • CASI’s FA Score: 0 green, 5 red.
According to our system of comparison, ATRA is a better buy in the long-term than CASI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 3 TA indicator(s) are bullish while CASI’s TA Score has 4 bullish TA indicator(s).

  • ATRA’s TA Score: 3 bullish, 3 bearish.
  • CASI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ATRA is a better buy in the short-term than CASI.

Price Growth

ATRA (@Biotechnology) experienced а +12.68% price change this week, while CASI (@Biotechnology) price change was -24.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.10%, and the average quarterly price growth was +53.89%.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATRA($91.1M) has a higher market cap than CASI($23.5M). ATRA YTD gains are higher at: -2.554 vs. CASI (-46.290). ATRA has higher annual earnings (EBITDA): 14.3M vs. CASI (-42.6M). ATRA has more cash in the bank: 22.3M vs. CASI (6.76M). ATRA has less debt than CASI: ATRA (17.7M) vs CASI (18.7M). ATRA has higher revenues than CASI: ATRA (189M) vs CASI (31.6M).
ATRACASIATRA / CASI
Capitalization91.1M23.5M388%
EBITDA14.3M-42.6M-34%
Gain YTD-2.554-46.2906%
P/E Ratio18.01N/A-
Revenue189M31.6M598%
Total Cash22.3M6.76M330%
Total Debt17.7M18.7M95%
FUNDAMENTALS RATINGS
ATRA vs CASI: Fundamental Ratings
ATRA
CASI
OUTLOOK RATING
1..100
7551
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3965
P/E GROWTH RATING
1..100
34100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CASI's Valuation (68) in the Biotechnology industry is in the same range as ATRA (74). This means that CASI’s stock grew similarly to ATRA’s over the last 12 months.

CASI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that CASI’s stock grew similarly to ATRA’s over the last 12 months.

CASI's SMR Rating (100) in the Biotechnology industry is in the same range as ATRA (100). This means that CASI’s stock grew similarly to ATRA’s over the last 12 months.

ATRA's Price Growth Rating (39) in the Biotechnology industry is in the same range as CASI (65). This means that ATRA’s stock grew similarly to CASI’s over the last 12 months.

ATRA's P/E Growth Rating (34) in the Biotechnology industry is significantly better than the same rating for CASI (100). This means that ATRA’s stock grew significantly faster than CASI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRACASI
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 17 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MAKAF0.090.02
+20.22%
Hardcore Discoveries Ltd
NEXCF0.140.01
+7.80%
NexTech3D.AI Corp.
BPZZF15.85N/A
N/A
Boston Pizza Royalties Income Fund
LIOPF9.13N/A
N/A
Lion Corp.
BDWBY4.24N/A
N/A
BUDWEISER BREWING CO APAC LTD.

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with GRI. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then GRI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
+5.45%
GRI - ATRA
40%
Loosely correlated
-2.50%
SLRX - ATRA
39%
Loosely correlated
+1.91%
FOLD - ATRA
34%
Loosely correlated
-4.78%
MOLN - ATRA
33%
Poorly correlated
N/A
XOMA - ATRA
33%
Poorly correlated
+1.18%
More

CASI and

Correlation & Price change

A.I.dvisor tells us that CASI and ATRA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ATRA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
-8.98%
ATRA - CASI
33%
Poorly correlated
+5.45%
RIGL - CASI
30%
Poorly correlated
-1.25%
VICP - CASI
29%
Poorly correlated
N/A
BTAI - CASI
29%
Poorly correlated
-11.15%
ADCT - CASI
27%
Poorly correlated
-2.87%
More